BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 7911272)

  • 1. Expression of c-erb B-2 oncogene product in persistent gestational trophoblastic disease.
    Cameron B; Gown AM; Tamimi HK
    Am J Obstet Gynecol; 1994 Jun; 170(6):1616-21; discussion 1621-2. PubMed ID: 7911272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of epidermal growth factor receptor-related family products in gestational trophoblastic diseases and normal placenta and its relationship with development of postmolar tumor.
    Tuncer ZS; Vegh GL; Fulop V; Genest DR; Mok SC; Berkowitz RS
    Gynecol Oncol; 2000 Jun; 77(3):389-93. PubMed ID: 10831347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.
    Fulop V; Mok SC; Genest DR; Szigetvari I; Cseh I; Berkowitz RS
    J Reprod Med; 1998 Feb; 43(2):101-10. PubMed ID: 9513871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of p53, BCL-2 and epidermal growth factor receptor protein expression in the partial and complete hydatidiform moles.
    Hussein MR
    Exp Mol Pathol; 2009 Aug; 87(1):63-9. PubMed ID: 19348791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-evacuation hCG glycoforms in uneventful complete hydatidiform mole and persistent trophoblastic disease.
    Thomas CM; Kerkmeijer LG; Ariaens HJ; van der Steen RC; Massuger LF; Sweep FC
    Gynecol Oncol; 2010 Apr; 117(1):47-52. PubMed ID: 20116088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P63 expression in hydropic abortion and gestational trophoblastic diseases.
    Ramalho LN; Maggiori MS; Ribeiro-Silva A; Peres LC
    Placenta; 2006; 27(6-7):740-3. PubMed ID: 16026831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of CA-125 in trophoblastic disease.
    Kohorn EI
    Gynecol Oncol; 2000 Jul; 78(1):39-42. PubMed ID: 10873407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of maspin in gestational trophoblastic disease.
    Li HW; Leung SW; Cheung AN; Yu MM; Chan LK; Wong YF
    Gynecol Oncol; 2006 Apr; 101(1):76-81. PubMed ID: 16271752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis in gestational trophoblastic disease is correlated with clinical outcome and Bcl-2 expression but not Bax expression.
    Wong SY; Ngan HY; Chan CC; Cheung AN
    Mod Pathol; 1999 Nov; 12(11):1025-33. PubMed ID: 10574599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The c-erbB-related oncoproteins in normal placenta and in gestational trophoblastic diseases (in vitro study)].
    Fülöp V; Végh G; Doszpod J
    Orv Hetil; 2001 Jun; 142(22):1147-54. PubMed ID: 11424588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinases and their inhibitors in gestational trophoblastic diseases and normal placenta.
    Vegh GL; Selcuk Tuncer Z; Fulop V; Genest DR; Mok SC; Berkowitz RS
    Gynecol Oncol; 1999 Nov; 75(2):248-53. PubMed ID: 10525381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-erbB-2 amplification and expression in gestational trophoblastic disease correlates with DNA content and karyotype.
    Bauer M; Horn LC; Kowalzik J; Mair W; Czerwenka K
    Gen Diagn Pathol; 1997 Nov; 143(2-3):185-90. PubMed ID: 9443575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p57(KIP2) immunohistochemical staining of gestational trophoblastic tumours does not identify the type of the causative pregnancy.
    Sebire NJ; Rees HC; Peston D; Seckl MJ; Newlands ES; Fisher RA
    Histopathology; 2004 Aug; 45(2):135-41. PubMed ID: 15279631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent trophoblast disease following partial molar pregnancy.
    Wielsma S; Kerkmeijer L; Bekkers R; Pyman J; Tan J; Quinn M
    Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):119-23. PubMed ID: 16638033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases.
    Shaarawy M; Darwish NA; Abdel-Aziz O
    J Soc Gynecol Investig; 1996; 3(1):39-46. PubMed ID: 8796806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a reliable marker of active neoplasia.
    Cole LA; Butler SA; Khanlian SA; Giddings A; Muller CY; Seckl MJ; Kohorn EI
    Gynecol Oncol; 2006 Aug; 102(2):151-9. PubMed ID: 16631241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia among women with partial molar pregnancies.
    Growdon WB; Wolfberg AJ; Feltmate CM; Goldstein DP; Genest DR; Chinchilla ME; Berkowitz RS; Lieberman ES
    J Reprod Med; 2006 Nov; 51(11):871-4. PubMed ID: 17165432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of pregnancies occurring before completion of human chorionic gonadotropin follow-up in patients with persistent gestational trophoblastic tumor.
    Tuncer ZS; Bernstein MR; Goldstein DP; Berkowitz RS
    Gynecol Oncol; 1999 Jun; 73(3):345-7. PubMed ID: 10366457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of plasma prolactin in breast cancer: comparison with the expression of c erb B-2 oncoprotein.
    Bhatavdekar JM; Patel DD; Sherbet GV; Giri DD; Karelia NH; Vora HH; Shah NG; Suthar TP; Nadkarni SP; Balar DB
    Eur J Surg Oncol; 1993 Oct; 19(5):409-13. PubMed ID: 8104829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gestational trophoblastic diseases: 4. Presentation with persistent low positive human chorionic gonadotropin test results.
    Cole LA; Khanlian SA; Giddings A; Butler SA; Muller CY; Hammond C; Kohorn E
    Gynecol Oncol; 2006 Aug; 102(2):165-72. PubMed ID: 16631243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.